Benzimidazole drugs and modulation of biotransformation enzymes

Research in Veterinary Science

Volumn 76, Issue 2, 2004, Pages 95-108

  Velik J ^a   Baliharova V ^a   Fink Gremmels, J ^b   Bull, S ^b   Lamka, J ^a   Skalova L ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Anthelmintic; Benzimidazole; Cytochrome P450; Enzyme induction; Enzyme inhibition; Proton pump inhibitors

Indexed keywords

ALBENDAZOLE; ASTEMIZOLE; BENOMYL; BENZIMIDAZOLE DERIVATIVE; CARBENDAZIM; CIMETIDINE; CYTOCHROME P450 1A; CYTOCHROME P450 2A6; CYTOCHROME P450 2B2; CYTOCHROME P450 2E1; CYTOCHROME P450 3A; DIAZEPAM; ETHINYLESTRADIOL; FEBANTEL; FENBENDAZOLE; FLUBENDAZOLE; LANSOPRAZOLE; MEBENDAZOLE; MIZOLASTINE; OMEPRAZOLE; OXFENDAZOLE; PANTOPRAZOLE; PHENYTOIN; RABEPRAZOLE; THEOPHYLLINE; TIABENDAZOLE; TIMOPRAZOLE; TRICLABENDAZOLE; UNINDEXED DRUG; WARFARIN;

ANTHELMINTIC ACTIVITY; CELL CULTURE; DRUG EFFICACY; DRUG INHIBITION; DRUG METABOLISM; DRUG STRUCTURE; DRUG TRANSFORMATION; DUODENUM ULCER; HUMAN; NONHUMAN; REFLUX ESOPHAGITIS; REVIEW; STOMACH ULCER; STRUCTURE ACTIVITY RELATION; ZOLLINGER ELLISON SYNDROME;

ANIMALIA;

EID: 1342302425     PISSN: 00345288     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rvsc.2003.08.005     Document Type: Review

References (117)

1. Aix, L., Rey-Grobellet, X., Larrieu, G., Lesca, P., Galtier, P., 1994. Thiabendazole is an inducer of cytochrome P4501A1 in cultured rabbit hepatocytes. Biochemical and Biophysical Research Communications 202, 1483-1489.
2. Asteinza, J., Camacho-Carranza, R., Reyes-Reyes, R.E., Dorado-González, V., Espinosa-Aguirre, J.J., 2000. Induction of cytochrome P450 enzymes by albendazole treatment in the rat. Environmental Toxicology and Pharmacology 9, 31-37.
3. Backlund, M., Weidolf, L., Ingelman-Sundberg, M., 1999. Structural and mechanistic aspects of transcriptional induction of cytochrome P450 1A1 by benzimidazole derivatives in rat hepatoma H4IIE cells. European Journal of Biochemistry 261, 66-71.
4. Baggot, J.D., McKellar, Q.A., 1994. The absorption, distribution and elimination of anthelmintic drugs: the role of pharmacokinetics. Journal of Veterinary Pharmacology and Therapeutics 17, 409-419.
5. Baliharová, V., Skálová, L., Maas, R.F.M., De Vrieze, G., Bull, S., Fink-Gremmels, J., 2003a. The effects of benzimidazole anthelmintics on P4501A in rat hepatocytes and HepG2 cells. Research in Veterinary Science 75, 61-69.
6. Baliharová, V., Skálová, L., Maas, R.F.M., De Vrieze, G., Bull, S., Fink-Gremmels, J., 2003b. The effects of benzimidazole anthelmintics on P4501A in rat hepatocytes and HepG2 cells. Comparison with thiabendazole and omeprazole. Journal of Pharmacy and Pharmacology 55, 773-781.
7. Bapiro, T.E., Andersson, T.B., Otter, C., Hasler, J.A., Masimirembwa, C.M., 2002. Cytochrome P-450 1A1/2 induction by antiparasitic drugs: Dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells. European Journal of Clinical Pharmacology 58, 537-542.
8. Barry, M., Feely, J., 1990. Enzyme induction and inhibition. Pharmacology and Therapeutics 48, 71-94.
9. Benchaoui, H.A., McKellar, Q.A., 1996. Interaction between fenbendazole and piperonyl butoxide: pharmacokinetic and pharmacodynamic implications. Journal of Pharmacy and Pharmacology 48, 753-759.
10. Benoit, E., Besse, S., Delatour, P., 1992. Effect of repeated doses of albendazole on enantiomerism of its sulfoxide metabolite in goats. American Journal of Veterinary Research 53, 1663-1665.
11. Boobis, A.R., Sesardic, D., Murray, B.P., Edwards, RJ., Singleton, A.M., Rich, K.J., Murray, S., De La Torre, R., Segura, J., Pelkonen, O., Pasanen, M., Kobayashi, S., Zhi-Guang, T., Davies, D.S., 1990. Species variation in the response of the cytochrome P-450-dependent monooxygenase system to inducers and inhibitors. Xenobiotica 20, 1139-1161.
12. Chauret, N., Gauthier, A., Martin, J., Nicoll-Griffith, D.A., 1997. In vitro comparison of cytochrome P450-mediated metabolic activities in human, dog, cat and horse. Drug Metabolism and Disposition 25, 1130-1136.
13. Coulet, M., Dacasto, M., Eeckhoutte, C., Larrieu, G., Sutra, J.F., Alvinerie, M., Macé, K., Pfeifer, A.M.A., Galtier, P., 1998. Identification of human and rabbit cytochromes P450 1A2 as major isoforms involved in thiabendazole 5-hydroxylation. Fundamental and Clinical Pharmacology 12, 225-235.
14. Coulet, M., Eeckhoutte, C., Larrieu, G., Sutra, J.F., Alvinerie, M., Macé, K., Pfeifer, A., Zucco, F., Stammati, A.L., De Angelis, I., Vignoli, A.L., Galtier, P., 2000. Evidence for cytochrome P4501A2-mediated protein covalent binding of thiabendazole and for its passive intestinal transport: use of human and rabbit derived cells. Chemico-Biological Interactions 127, 109-124.
15. Cristofol, C., Virkel, G., Alvarez, L., Arboix, M., Lanusse, C.E., 2000. Comparative disposition of ricobendazole enantiomers after intravenous and subcutaneous administration of a racemic formulation to calves. Biopharmaceutics and Drug Disposition 21, 303-311.
16. Csiko, G.Y., Bandidi, G.Y., Semjen, G., Laczay, P., Sandor, G.V., Lehel, J., Fekete, J., 1996. Metabolism and pharmacokinetics of albendazole after oral administration to chickens. Journal of Veterinary Pharmacology and Therapeutics 19, 322-325.
17. Curi-Pedrosa, R., Daujat, M., Pichard, L., Ourlin, J.C., Clair, P., Gervot, L., Lesca, P., Domergue, J., Joyeux, H., Fourtanier, G., Maurel, P., 1994. Omeprazole and lansoprazole are mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture. The Journal of Pharmacology and Experimental Therapeutics 269, 384-392.
18. Dalvi, R.R., Gawai, K.R., Dalvi, P.S., 1991. Lack of in vivo and in vitro effects of fenbendazole on phase I and phase II biotransformation enzymes in rats, mice and chicken. Veterinary and Human Pharmacology 33, 548-551.
19. Daujat, M., Peryt, B., Lesca, P., Fourtanier, G., Domerque, J., Maurel, P., 1992. Omeprazole, an inducer of human CYP1A1 and 1A2, is not a ligand for the Ah receptor. Biochemical and Biophysical Research Communications 188, 820-825.
20. Delatour, P., Benoit, E., Besse, S., Soraci, A., 1994. Drug chirality, its significance in veterinary pharmacology and therapeutics. Revue de Medicine Veterinaire 145, 551-561.
21. Delatour, P., Benoit, E., Lechenet, J., Besse, S., 1990. Pharmacokinetics in sheep and cattle of albendazole administered by an intraruminal slow release capsule. Research in Veterinary Science 48, 271-275.
22. Delatour, P., Benoit, E., Besse, S., Boukraa, A., 1991a. Comparative enantioselectivity in the sulphoxidation of albendazole in man, dogs, and rats. Xenobiotica 21, 217-221.
23. Delatour, P., Garnier, F., Benoit, E., Caude, I., 1991b. Chiral behaviour of the metabolite albendazole sulphoxide in sheep, goats and cattle. Research in Veterinary Science 50, 134-138.
24. Delescluse, C., Ledirac, N., Li, R., Piechocki, M.P., Hines, R.N., Gidrol, X., Rahmani, R., 2001. Induction of cytochrome P450 1A1 gene expression, oxidative stress, and genotoxicity by carbaryl and thiabendazole in transfected human HepG2 and lymphoblastoid cells. Biochemical Pharmacology 61, 399-407.
25. Diaz, D., Fabre, I., Daujat, M., Saint Aubert, B., Bories, P., Michel, H., Maurel, P., 1990. Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450. Gastroenterology 99, 737-747.
26. Douch, P.G., Buchanan, L.L., 1979. Some properties of the sulphoxidases and sulphoxide reductases of the cestode Moniezia expansa, the nematode Ascaris suum and mouse liver. Xenobiotica 9, 675-679.
27. Dubois, M., De Waziers, I., Thome, J.P., Kremers, P., 1996. P450 induction by Aroclor 1254 and 3,3′, 4,4′ tetrachlorobiphenyl in cultured hepatocytes from rat, quail and man: interspecies comparison. Comparative Biochemistry and Physiology 113, 51-59.
28. Dzeletovic, N., McGuire, J., Daujat, M., Tholander, J., Ema, M., Fujii-Kuriyama, Y., Bergman, J., Maurel, P., Poellinger, L., 1997. Regulation of dioxin receptor function by omeprazole. Journal of Biological Chemistry 272, 12705-12713.
29. Fargetton, X., Galtier, P., Delatour, P., 1986. Sulfoxidation of albendazole by a cytochrome P450-independent monooxygenase from rat liver microsomes. Veterinary Research Communications 10, 317-324.
30. Fink-Gremmels, J., van Miert, A.S.J.P.A.M., 1994. Veterinary drugs: disposition, biotransfomation and risk evaluation. Analyst 119, 2521-2528.
31. Friendship, R.M., Melnichouk, S.I., Dewey, C.E., 2000. The use of omeprazole to alleviate stomach ulcers in swine during periods of feed withdrawal. Canadian Veterinary Journal 41, 925-928.
32. Frötschl, R., Chichmanov, L., Kleeberg, U., Hildebrandt, A.G., Roots, I., Brockmöller, J., 1998. Prediction of aryl hydrocarbon receptor-mediated enzyme induction of drugs and chemicals by mRNA quantification. Chemical Research in Toxicology 11, 1447-1452.
33. Fuchs, W., Sennewald, R., Klotz, U., 1994. Lansoprazole does not affect the bioavailability of oral contraceptives. British Journal of Clinical Pharmacology 38, 376-380.
34. Galtier, P., 1991. Metabolism of benzimidazoles and enzymatic induction activity. Revue de Medicine Veterinaire 142, 633-636.
35. Galtier, P., Alvinerie, M., Steimer, J.L., Francheteau, P., Plusquellec, Y., Houin, G., 1991. Simultaneous pharmacokinetic modeling of drug and two metabolites: Application to albendazole in sheep. Journal of Pharmaceutical sciences 80, 3-10.
36. Galtier, P., Rey-Grobellet, X., Alvinerie, M., Pineau, T., 1997. Compared cytochrome P450 induction properties of benzimidazole anthelminties by using cultured rabbit hepatocytes. Journal of Veterinary Pharmacology and Therapeutics 10, 89.
37. Gleizes, C., Eeckhoutte, C., Pineau, T., Alvinerie, M., Galtier, P., 1991. Inducing effect of oxfendazole on cytochrome P450IA2 in rabbit liver. Consequences on cytochrome P450 dependent monooxygenases. Biochemical Pharmacology 41, 1813-1820.
38. Gleizes-Escala, C., Lesca, P., Larrieu, G., Dupuy, J., Pineau, T., Galtier, P., 1996. Effect of exposure of rabbit hepatocytes to sulfur-containing anthelmintics (oxfendazole and fenbendazole) on cytochrome P4501A1 expression. Toxicology in Vitro 10, 129-139.
39. Granneman, G.R., Karol, M.D., Locke, C.S., Cavanaugh, J.H., 1995. Pharmacokinetic interaction between lansoprazole and theophylline. Therapeutic Drug Monitoring 17, 460-464.
40. Grove-White, D.H., Noble, P.J.M., Taylor, D.J., Walmsley, P.J., 2001. Drug acting on the gastro-intestinal system. In: Bishop, J. (Ed.), The Veterinary Formulary, Fifth ed. Pharmaceutical Press, London, pp. 324-326.
41. Gugler, R., Jensen, J.C., 1985. Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology 89, 1235-1241.
42. Hitzl, M., Klein, K., Zanger, U.M., Fritz, P., Nussler, A.K., Neuhaus, P., Fromm, M.F., 2003. Influence of omeprazole on multidrug resistant protein 3 expression in human liver. Journal of Pharmacology and Experimental Therapeutics 304, 524-530.
43. Horn, J., 2000. The proton-pump inhibitors: similarities and differences. Clinical Therapeutics 22, 266-280.
44. Humphries, T.J., 1991. Clinical implications of drug interactions with the cytochrome P-450 enzyme system associated with omeprazole. Digestive Diseases and Sciences 36, 1665-1669.
45. Jacobs, D.E.J., Taylor, M.A., 2001. Drugs used in the treatment and control of parasitic infections. In: Bishop, J. (Ed.), The Veterinary Formulary, Fifth ed. Pharmaceutical Press, London, pp. 219-245.
46. Kikuchi, H., Hossain, A., Sagami, S., Ikawa, S., Watanabe, M., 1995. Different inducibility of cytochrome P-4501A1 mRNA of human and mouse by omeprazole in culture cells. Archives of Biochemistry and Biophysics 316, 649-656.
47. Kikuchi, H., Hossain, A., Yoshida, H., Kobayashi, S., 1998. Induction of cytochrome P-450 1A1 by omeprazole in human HepG2 cells is protein tyrosine kinase-dependent and is not inhibited by α-naphthoflavone. Archives of Biochemistry and Biophysics 358, 351-358.
48. Kikuchi, H., Kato, H., Mizuno, M., Hossain, A., Ikawa, S., Miyazaki, J., Watanabe, M., 1996. Differences in inducibility of CYP1A1-mRNA by benzimidazole compounds between human and mouse cells: Evidences of a human-specific signal transduction pathway for CYP1A1 induction. Archives of Biochemistry and Biophysics 334, 235-240.
49. Kleeberg, U., Frötschl, R., Krusekopf, S., Brockmöller, J., Roots, I., Ruckpaul, K., Hildebrandt, A.G., 1999. Induction of CYP1A by various benzimidazoles and its significance in administrative drug regulation. Drug Metabolism Reviews 31, 381-392.
50. Ko, J.W., Jang, I.J., Shin, J.G., Nam, S.K., Shin, S.G., Flockhart, D.A., 1999. Theophylline pharmacokinetics are not altered by lansoprazole in CYP2C19 poor metabolizers. Clinical Pharmacology and Therapeutics 65, 606-614.
51. Kokufu, T., Ihara, N., Sugioka, N., Koyama, H., Ohta, T., Mori, S., Nakajima, K., 1995. Effects of lansoprazole on pharmacokinetics and metabolism of theophylline. European Journal of Clinical Pharmacology 48, 391-395.
52. Krusekopf, S., Kleeberg, U., Hildebrandt, A.G., Ruckpaul, K., 1997. Effects of benzimidazole derivatives on cytochrome P450 1A1 expression in a human hepatoma cell line. Xenobiotica 27, 1-9.
53. Krusekopf, S., Roots, I., Hildebrandt, A.G., Kleeberg, U., 2003a. Time-dependent transcriptional induction of CYP1A1, CYP1A2 and CYP1B1 mRNAs by H+/K+-ATPase inhibitors and other xenobiotics. Xenobiotica 33, 107-118.
54. Krusekopf, S., Roots, I., Kleeberg, U., 2003b. Differential drug-induced mRNA expression of human CYP3A4 compared to CYP3A5, CYP3A7 and CYP3A43. European Journal of Pharmacology 466, 7-12.
55. Landes, B.D., Petite, J.P., Flouvat, B., 1995. Clinical pharmacokinetics of lansoprazole. Clinical Pharmacokinetics 28, 458-470.
56. Lanusse, C.E., Gascon, L.H., Prichard, R.K., 1995. Comparative plasma disposition kinetics of albendazole, fenbendazole, oxfendazole and their metabolites in adult sheep. Journal of Veterinary Pharmacology and Therapeutics 18, 196-203.
57. Lewis, D.F.V., Lake, B.J., 1998. Molecular modelling and quantitative structure-activity relationship studies on the interaction of omeprazole with cytochrome P450 isozymes. Toxicology 125, 31-44.
58. Li, T., Quiao, G.L., Hu, G.Z., Meng, F.D., Qui, Y.S., Zhang, X.Y., Guo, W.X., Yie, H.L., Li, S.F., Li, S.Y., 1995. Comparative plasma and tissue pharmacokinetics and drug residue profiles of different chemotherapeutants in fowls and rabbits. Journal of Veterinary Pharmacology and Therapeutics 18, 260-273.
59. Lu, C.H., Li, A.P., 2001. Species comparison in P450 induction: Effects of dexamethazone, omeprazole, and rifampin on P450 isoforms 1A and 3A in primary cultured hepatocytes from man, Sprague-Dawley rat, minipig, and beagle dog. Chemico-Biological Interactions 134, 271-281.
60. Marriner, S.E., Bogan, J.A., 1980. Pharmacokinetics of albendazole in sheep. American Journal of Veterinary Research 41, 1126-1129.
61. Marriner, S.E., Morris, D.L., Dickson, B., Bogan, J.A., 1986. Pharmacokinetics of albendazole in man. European Journal of Clinical Pharmacology 30, 705-708.
62. Masubuchi, N., Hakusui, H., Okazaki, O., 1997a. Effects of pantoprazole on xenobiotic metabolizing enzymes in rat liver microsomes: A comparison with other proton pump inhibitors. Drug Metabolism and Disposition 25, 584-589.
63. Masubuchi, N., Hakusui, H., Okazaki, O., 1997b. Effects of proton pump inhibitors on thyroid hormone metabolism in rats. A comparison of UDP-glucuronyltransferase induction. Biochemical Pharmacology 54, 1225-1231.
64. Masubuchi, N., Okazaki, O., 1997. An evaluation of the CYP1A induction potential of pantoprazole in primary rat hepatocytes: A comparison with other proton pump inhibitors. Chemico-Biological Interactions 107, 63-74.
65. Masubuchi, N., Li, A.P., Okazaki, O., 1998. An evaluation of the cytochrome P450 induction potential of pantoprazole in primary human hepatocytes. Chemico-Biological Interactions 114, 1-13.
66. McCracken, R.O., Lipkowitz, K.B., 1990. Experimental and theoretical studies of albendazole, oxibendazole, and tioxidazole. Journal of Parasitology 76, 180-185.
67. McDonnell, W.M., Scheiman, J.M., Traber, P.G., 1992. Induction of cytochrome P450IA genes (CYP1A) by omeprazole in the human alimentary tract. Gastroenterology 103, 1509-1516.
68. McKellar, Q.A., Gokbulut, C., Muzandu, K., Benchaoui, H., 2002. Fenbendazole pharmacokinetics, metabolism, and potentiation in horses. Drug Metabolism and Disposition 30, 1230-1239.
69. Mehta, D.K. (Ed.), 2000. Anthelmintics. British National Formulary, 2000. British Medical Association, London, pp. 309-311.
70. Merrill, J.C., Beck, D.J., Kaminski, D.A., Li, A.P., 1995. Polybrominated biphenyl induction of cytochrome P450 mixed function oxidase activity in primary rat and human hepatocytes. Toxicology 99, 147-152.
71. Moroni, P., Buronfosse, T., Longin-Sauvageon, C., Delatour, P., Benoit, E., 1995. Chiral sulfoxidation of albendazole by the flavin adenine dinucleotide-containing and cytochrome P450-dependent monooxygenases from rat liver microsomes. Drug Metabolism and Disposition 23, 160-165.
72. Murray, M., Hudson, A.M., Yassa, V., 1992. Hepatic microsomal metabolism of the anthelmintic benzimidazole fenbendazole: enhanced inhibition of cytochrome P450 reactions by oxidized metabolites of the drug. Chemical Research in Toxicology 5, 60-66.
73. Nagy, J., Shipper, H.G., Koopmans, R.P., Butter, J.J., Van Boxtel, C.J., Kager, P.A., 2002. Effect of grapefruit juice or cimetidine coadministration on albendazole bioavailability. American Journal of Tropical Medicine and Hygiene 66, 260-263.
74. Nebbia, C., 2001. Biotransformation enzymes as determinants of xenobiotic toxicity in domestic animals. The Veterinary Journal 161, 238-252.
75. Nicolas, J.M., Whomsley, R., Collart, P., Roba, J., 1999. In vitro inhibition of human liver drug metabolising enzymes by second generation antihistamines. Chemico-Biological Interactions 123, 63-79.
76. Nishimura, M., Yoshitsugu, H., Naito, S., Hiraoka, I., 2002. Evaluation of gene induction of drug-metabolizing enzymes and transporters in primary culture of human hepatocytes using high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi 122, 339-361.
77. Nousbaum, J.B., Berthou, F., Carlhant, D., Riche, C., Robaszkiewicz, M., Gouerou, H., 1994. Four-week treatment with omeprazole increases the metabolism of caffeine. American Journal of Gastroenterology 89, 371-375.
78. Okey, A.B., 1990. Enzyme induction in the cytochrome P-450 system. Pharmacology and Therapeutics 45, 241-298.
79. Paolini, M., Mesirca, R., Pozzetti, L., Sapone, A., Cantelli-Forti, G., 1995. Induction of CYP2B1 mediated pentoxyresorufin O-dealkylase activity in different species, sex and tissue by prototype 2B1-inducers. Chemico-Biological Interactions 95, 127-139.
80. Pelkonen, O., Mäenpää, J., Taavitsainen, P., Rautio, A., Raunio, H., 1998. Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica 28, 1203-1253.
81. Penicaut, B., Maugein, P., Maisonneuve, H., Rossignol, J.F., 1983. Pharmacokinetics and urinary metabolism of albendazole in man. Bulletin de la Societe de Pathologie Exotique et de Ses Filiales 76, 698-708.
82. Pichard-Garcia, L., Whomsley, R., Daujat, M., Maurel, P., Setoyama, T., Humphries, T.J., 2000. Comparative effects of rabeprazole and omeprazole on the inducibility of cytochrome P450-1A and cytochrome P450-3A isoenzymes in human hepatocytes, and effects on cyclosporin metabolism in human liver microsomes. Clinical Drug Investigation 20, 245-254.
83. Plumb, D.J. (Ed.), 1999. Veterinary Drug Handbook, Third ed. Iowa State University press, Ames.
84. Prichard, R.K., Hennessy, D.R., Steel, J.W., Lacey, E., 1985. Metabolite concentrations in plasma following treatment of cattle with five anthelmintics. Research in Veterinary Science 39, 173-178.
85. Puri, S., Kohli, K.K., 1995. Differences in hepatic drug metabolizing enzymes and their response to lindane in rat, rabbit, and monkey. Pharmacology and Toxicology 77, 136-141.
86. Radice, S., Marabini, L., Gervasoni, M., Ferraris, M., Chiesara, E., 1997. Carbendazim and n-butyl-isocyanate: Metabolites responsible for benomyl double action on cytochrome P450 in HepG2 cells. Toxicology 123, 135-142.
87. Rawden, H.C., Kokwaro, G.O., Ward, S.A., Edwards, G., 2000. Relative contribution of cytochrome P-450 and flavine-containing monooxygenases to the metabolism of albendazole by human liver microsomes. British Journal of Clinical Pharmacology 49, 313-322.
88. Rey-Grorbellet, X., Eeckhoutte, C., Sutra, J.F., Alvinerie, M., Galtier, P., 1996a. Major involvement of rabbit liver cytochrome P4501A in thiabendazole 5-hydroxylation. Xenobiotica 26, 765-778.
89. Rey-Grobellet, X., Ferre, N., Eeckhoutte, C., Larrieu, G., Pineau, T., Galtier, P., 1996b. Structural requirements for the induction of cytochrome P450 by benzimidazole anthelmintic derivatives in cultured rabbit hepatocytes. Biochemical and Biophysical Research Communications 220, 789-794.
90. Rolin, S., Souhaili-El Amri, H., Batt, A.M., Levy, M., Bagrel, D., Siest, G., 1989. Study of the in vitro bioactiviation of albendazole in human liver microsomes and hepatoma cell lines. Cell Biology and Toxicology 5, 1-14.
91. Rost, K.L., Roots, I., 1994. Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: coincidence with plasma clearance and breath test. Clinical Pharmacology and Therapeutics 55, 402-411.
92. Rost, K.L., Brösicke, H., Brockmöller, J., Scheffler, M., Helge, H., Roots, I., 1992. Increase of cytochrome P4501A2 activity by omeprazole: Evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin. Clinical Pharmacology and Therapeutics 52, 170-180.
93. Rost, K.L., Brösicke, H., Heinemeyer, G., Roots, I., 1994. Specific and dose-dependent enzyme induction by omeprazole in human beings. Hepatology 20, 1204-1212.
94. Rost, K.L., Fuhr, U., Thomsen, T., Zaigler, M., Brockmöller, J., Bohnemeier, H., Roots, I., 1999. Omeprazole weakly inhibits CYP1A2 activity in man. International Journal of Clinical Pharmacology and Therapeutics 37, 567-574.
95. Shih, H., Pickwell, G.V., Guenette, D.K., Bilir, B., Quattrochi, L.C., 1999. Species differences in hepatocyte induction of CYP1A1 and CYP1A2 by omeprazole. Human and Experimental Toxicology 18, 95-105.
96. Shimada, T., Mimura, M., Inoue, K., Nakamura, S., Oda, H., Ohmori, S., Yamazaki, H., 1997. Cytochrome P450-dependent drug oxidation activities in liver microsomes of various animal species including rats, guinea pigs, dogs, monkeys, and humans. Archives of Toxicology 71, 401-408.
97. Souhaili-El Amri, H., Fargetton, X., Delatour, P., Batt, A.M., 1987. Sulphoxidation of albendazole by the FAD-containing and cytochrome P-450 dependent mono-oxygenases from pig liver microsomes. Xenobiotica 17, 1159-1168.
98. Souhaili-El Amri, H., Fargetton, X., Benoit, E., Totis, M., Batt, A.M., 1988a. Inducing effect of albendazole on rat liver drug-metabolizing enzymes and metabolite pharmacokinetics. Toxicology and Applied Pharmacology 92, 141-149.
99. Souhaili-El Amri, H., Mothe, O., Totis, M., Masson, C., Batt, A.M., Delatour, P., Siest, G., 1988b. Albendazole sulfonation by rat liver cytochrome P-450c. The Journal of Pharmacology and Experimental Therapeutics 246, 758-764.
100. Steinijans, V.W., Huber, R., Hartmann, M., Zech, K., Bliesath, H., Wurst, W., Radtke, H.W., 1994. Lack of pantoprazole drug interactions in man. International Journal of Clinical Pharmacology and Therapeutics 32, 385-399.
101. Tebbe, M.J., Jensen, C.B., Spitzer, W.A., Franklin, R.B., George, M.Ch., Phillips, D.L., 1999. The effects of antirhino- and entero-viral vinylacetylene benzimidazoles on cytochrome P450 function and hepatic porphyrin levels in mice. Antiviral Research 42, 25-33.
102. Testa, B., 1995. Biochemistry of redox reactions. In: Testa, B., Caldwell, J. (Eds.), The metabolism of drugs and other xenobiotics. Academic Press, London.
103. The Gentest homepage on URL: http://www.gentest.com.
104. Tocco, D.J., 1964. The metabolic fate of thiabendazole in sheep. Journal of Medicinal Chemistry 7, 405-753.
105. Tucker, G.T., 1994. The interaction of proton pump inhibitors with cytochromes P450. Alimentary Pharmacology and Therapeutics 8, 33-38.
106. van't Klooster, G.A.E., Horbach, G.J.M.J., Natsuhori, M., Blaauboer, B.J., Noordhoek, J., van Miert, A.S.J.P.A.M., 1993. Hepatic cytochrome P450 induction in goats. Biochemical Pharmacology 45, 113-122.
107. Vatistas, N.J., Snyder, J.R., Nieto, J., Thompson, D., Pollmeier, M., Holste, J., 1999. Acceptability of a paste formulation and efficacy of high dose omeprazole in healing gastric ulcers in horses maintained in race training. Equine Veterinary Journal 29, 71-76.
108. Villaverde, C., Alvarez, A.I., Redondo, P., Voces, J., Del Estal, J.L., Prieto, J.G., 1995. Small intestinal sulphoxidation of albendazole. Xenobiotica 25, 433-441.
109. Ward, S.A., Mihaly, G.W., Tjia, J.F., Back, D.J., 1985. The effect of some benzimidazoles on the disposition of antipyrine and tolbutamide from the rat isolated perfused liver. Journal of Pharmacy and Pharmacology 37, 62-64.
110. Weaver, R.J., Thompson, S., Smith, G., Dickins, M., Elcombe, C.R., Mayers, R.T., Burke, M.D., 1994. A comparative study of constitutive and induced alkoxyresorufin O-dealkylation and individual cytochrome P450 forms in cynomolgus monkey (Macaca fascicularis), human, mouse, rat, and hamster liver microsomes. Biochemical Pharmacology 47, 763-773.
111. WHO, 2001. ATC Classification and DDD Assignment, fourth edition. Oslo, WHO Collaborating Centre for Drug Statistics Methodology.
112. Yasuda, S., Harai, Y., Tomono, Y., Nakai, H., Yamato, C., Manabe, K., Kobayashi, K., Chiba, K., Ishizaki, T., 1995. Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4′-hydroxylation status. Clinical Pharmacology and Therapeutics 58, 143-154.
113. Yoneyama, M., Ichikawa, H., 1986. Irreversible in vivo and in vitro binding of thiabendazole to tissue protein of pregnant mice. Food and Chemical Toxicology 24, 1283-1286.
114. Zomorodi, K., Houston, J.B., 1995. Effect of omeprazole on diazepam disposition in rat: In vitro and in vivo studies. Pharmacological Research 12, 1642-1646.
115. Zomorodi, K., Houston, J.B., 1996. Diazepam-omeprazole inhibition interaction: An in vitro investigation using human liver microsomes. British Journal of Clinical Pharmacology 42, 157-162.
116. Zomorodi, K., Houston, J.B., 1997. Selectivity of omeprazole inhibition towards rat liver cytochromes P450. Xenobiotica 27, 49-58.
117. Zweers-Zeilmaker, W.M., 1998. Effects of non steroidal anti-inflammatory drugs and sulfonamides on hepatic cytochrome P4502C activity in vitro in goats and cattle. Journal of Veterinary Pharmacology and Therapeutics 21, 154-157.